Vaishali Sanchorawala, MD | Boston ...

Dr. Vaishali Sanchorawala, MD

Claim this profile

Boston Medical Center

Studies Amyloidosis
Studies AL Amyloidosis
5 reported clinical trials
9 drugs studied

Area of expertise

1

Amyloidosis

Vaishali Sanchorawala, MD has run 4 trials for Amyloidosis. Some of their research focus areas include:

t(11;14) positive
Stage I
Stage II
2

AL Amyloidosis

Vaishali Sanchorawala, MD has run 3 trials for AL Amyloidosis. Some of their research focus areas include:

t(11;14) positive
Stage I
Stage II

Affiliated Hospitals

Image of trial facility.

Boston Medical Center

Image of trial facility.

Boston University Medical Center

Clinical Trials Vaishali Sanchorawala, MD is currently running

Image of trial facility.

Venetoclax + Ixazomib + Dexamethasone

for AL Amyloidosis

This trial tests a combination of venetoclax, ixazomib citrate, and dexamethasone in patients with difficult-to-treat light chain amyloidosis. Venetoclax alone has shown promise in treating this condition, indicating its potential effectiveness and safety. The drugs work together to kill cancer cells and reduce inflammation.

Recruiting

1 award

Phase 1

22 criteria

Image of trial facility.

Chemotherapy + Stem Cell Transplant

for Amyloidosis

This phase III trial compares the effect of adding a stem cell transplant with melphalan after completing chemotherapy with daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD) versus chemotherapy with Dara-VCD alone for treating patients with newly diagnosed amyloid light chain (AL) amyloidosis. Melphalan is a chemotherapy given prior to a stem cell transplant. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. The stem cells are then returned to the patients to replace the blood forming cells that were destroyed by the chemotherapy. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs, such as cyclophosphamide and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to lower the body's immune response to help stop the growth of cancer cells. Giving a stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in patients with newly diagnosed AL amyloidosis.

Recruiting

2 awards

Phase 3

3 criteria

More about Vaishali Sanchorawala, MD

Clinical Trial Related

4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Vaishali Sanchorawala, MD has experience with

  • Daratumumab
  • Dexamethasone
  • Pomalidomide
  • STI-6129
  • Daratumumab/rHuPH20
  • Lenalidomide

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Vaishali Sanchorawala, MD specialize in?

Is Vaishali Sanchorawala, MD currently recruiting for clinical trials?

Are there any treatments that Vaishali Sanchorawala, MD has studied deeply?

What is the best way to schedule an appointment with Vaishali Sanchorawala, MD?

What is the office address of Vaishali Sanchorawala, MD?

Is there any support for travel costs?